Can an existing drug win against aggressive breast cancer?

According to recent studies, breast cancers are the second most commonly diagnosed type of cancer among women in the United States.

Triple-negative breast cancer is a resilient and especially aggressive subtype, accounting for approximately 15 percent of all diagnoses of breast cancer.

Triple-negative breast cancer is resistant to the commonest type of therapy currently applied: chemotherapy. This is partly due to the sheer endurance of stem-like cancer cells, which promote the formation of new tumors.

For this reason, scientists are permanently on the lookout for better, more effective treatment options that will prevent the migration of cancer cells within the body.

To read the full article, click HERE

Written by Maria Cohut for Medical News Today

(Photo credit www.medicalnewstoday.com)